Identification of a Gene Signature That Predicts Dependence upon YAP/TAZ-TEAD

Ryan Kanai,Emily Norton,Patrick Stern,Richard O. Hynes,John M. Lamar

DOI: https://doi.org/10.3390/cancers16050852

2024-02-21

Cancers

Abstract:Targeted therapies are effective cancer treatments when accompanied by accurate diagnostic tests that can help identify patients that will respond to those therapies. The YAP/TAZ-TEAD axis is activated and plays a causal role in several cancer types, and TEAD inhibitors are currently in early-phase clinical trials in cancer patients. However, a lack of a reliable way to identify tumors with YAP/TAZ-TEAD activation for most cancer types makes it difficult to determine which tumors will be susceptible to TEAD inhibitors. Here, we used a combination of RNA-seq and bioinformatic analysis of metastatic melanoma cells to develop a YAP/TAZ gene signature. We found that the genes in this signature are TEAD-dependent in several melanoma cell lines, and that their expression strongly correlates with YAP/TAZ activation in human melanomas. Using DepMap dependency data, we found that this YAP/TAZ signature was predictive of melanoma cell dependence upon YAP/TAZ or TEADs. Importantly, this was not limited to melanoma because this signature was also predictive when tested on a panel of over 1000 cancer cell lines representing numerous distinct cancer types. Our results suggest that YAP/TAZ gene signatures like ours may be effective tools to predict tumor cell dependence upon YAP/TAZ-TEAD, and thus potentially provide a means to identify patients likely to benefit from TEAD inhibitors.

oncology

What problem does this paper attempt to address?

The main objective of this paper is to identify a gene signature that can predict the dependency of cancer cells on the YAP/TAZ-TEAD signaling pathway. Specifically, the research team aims to use this gene signature to determine which patients' tumors might benefit from therapies targeting YAP/TAZ-TEAD.

To achieve this goal, the researchers first developed a YAP/TAZ gene signature in metastatic melanoma cells. They found that the genes in this signature are regulated by TEAD in multiple melanoma cell lines, and the expression levels of these genes are closely related to the activation status of YAP/TAZ in human melanomas.

By analyzing DepMap dependency data, the researchers further validated that this YAP/TAZ gene signature can predict the dependency of melanoma cells on YAP/TAZ or TEAD. Notably, this predictive capability is not limited to melanoma; it also showed good predictive performance when tested on cell lines encompassing over 1000 different cancer types.

In summary, the YAP/TAZ-TEAD gene signature proposed in this study has the potential to become an effective tool for predicting whether tumor cells depend on the YAP/TAZ-TEAD signaling pathway. This could help identify patient groups that might benefit from TEAD inhibitor therapies. This is particularly important for TEAD inhibitors currently in clinical trials, as being able to identify tumors that are likely to respond to these drugs in advance would significantly increase the success rate of the treatment.